Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


COVID Reference, 4th edition, 372 pages

+ the daily Top 10


  Breast Cancer

  Free Subscription


Articles published in Oncol Rep

Retrieve available abstracts of 148 articles:
HTML format



Single Articles


    June 2020
  1. LI C, Li X, Li G, Sun L, et al
    Identification of a prognosisassociated signature associated with energy metabolism in triplenegative breast cancer.
    Oncol Rep. 2020 Jun 23. doi: 10.3892/or.2020.7657.
    PubMed     Abstract available


  2. SHI Y, Wang M, Wang P, Zhang T, et al
    Alisol A is potentially therapeutic in human breast cancer cells.
    Oncol Rep. 2020 Jun 22. doi: 10.3892/or.2020.7654.
    PubMed     Abstract available


  3. ZHAO Y, Onda K, Sugiyama K, Yuan B, et al
    [Corrigendum] Antitumor effects of arsenic disulfide on the viability, migratory ability, apoptosis and autophagy of breast cancer cells.
    Oncol Rep. 2020 Jun 19. doi: 10.3892/or.2020.7653.
    PubMed     Abstract available


    April 2020
  4. SONG Y, He L, Wang Y, Wu Q, et al
    Molecularly targeted therapy and immunotherapy for hormone receptorpositive/human epidermal growth factor receptor 2negative advanced breast cancer (Review).
    Oncol Rep. 2020 Apr 21. doi: 10.3892/or.2020.7589.
    PubMed     Abstract available


  5. CHEN L, Zhang S, Shen Y, Qi L, et al
    Thymusexpressed chemokine secreted by breast cancer cells promotes metastasis and inhibits apoptosis.
    Oncol Rep. 2020 Apr 3. doi: 10.3892/or.2020.7575.
    PubMed     Abstract available


    March 2020
  6. ZUO Y, Xu H, Chen Z, Xiong F, et al
    17AAG synergizes with Belinostat to exhibit a negative effect on the proliferation and invasion of MDAMB231 breast cancer cells.
    Oncol Rep. 2020 Mar 26. doi: 10.3892/or.2020.7563.
    PubMed     Abstract available


  7. DING Y, Ma M, Li Q, Gao S, et al
    Clinical significance of sHER2ECD and calpain10 expression in tumor tissues of patients with breast cancer.
    Oncol Rep. 2020 Mar 26. doi: 10.3892/or.2020.7564.
    PubMed     Abstract available


  8. GAO X, Bao H, Liu L, Zhu W, et al
    Systematic analysis of lysine acetylome and succinylome reveals the correlation between modification of H2A.X complexes and DNA damage response in breast cancer.
    Oncol Rep. 2020 Mar 19. doi: 10.3892/or.2020.7554.
    PubMed     Abstract available


  9. HAN R, Zhao J, Lu L
    MicroRNA34a expression affects breast cancer invasion in vitro and patient survival via downregulation of E2F1 and E2F3 expression.
    Oncol Rep. 2020 Mar 18. doi: 10.3892/or.2020.7549.
    PubMed     Abstract available


  10. SEGURA-BAUTISTA D, Olivares A, Casas-Gonzalez P, Bonilla E, et al
    GPR30 expression and function in breast cancer cells are induced through a cisacting element targeted by ETS factors.
    Oncol Rep. 2020 Mar 10. doi: 10.3892/or.2020.7540.
    PubMed     Abstract available


  11. XIONG X, Feng Y, Li L, Yao J, et al
    Long noncoding RNA SNHG1 promotes breast cancer progression by regulation of LMO4.
    Oncol Rep. 2020 Mar 4. doi: 10.3892/or.2020.7530.
    PubMed     Abstract available


    February 2020
  12. YI D, Wang R, Shi X, Xu L, et al
    METTL14 promotes the migration and invasion of breast cancer cells by modulating N6methyladenosine and hsamiR146a5p expression.
    Oncol Rep. 2020 Feb 24. doi: 10.3892/or.2020.7515.
    PubMed     Abstract available


    January 2020
  13. LI C, Wang A, Chen Y, Liu Y, et al
    MicroRNA2995p inhibits cell metastasis in breast cancer by directly targeting serine/threonine kinase 39.
    Oncol Rep. 2020 Jan 31. doi: 10.3892/or.2020.7486.
    PubMed     Abstract available


  14. AL-YOUSEF N, Shinwari Z, Al-Shahrani B, Al-Showimi M, et al
    Curcumin induces reexpression of BRCA1 and suppression of gamma synuclein by modulating DNA promoter methylation in breast cancer cell lines.
    Oncol Rep. 2020 Jan 20. doi: 10.3892/or.2020.7473.
    PubMed     Abstract available


  15. ZHANG Z, Li Z, Deng M, Liu B, et al
    Downregulation of GPSM2 is associated with primary resistance to paclitaxel in breast cancer.
    Oncol Rep. 2020 Jan 17. doi: 10.3892/or.2020.7471.
    PubMed     Abstract available


  16. DUAN Z, Andrews NP, Chen CZ, Fan M, et al
    Targeting bromodomain protein ANCCA/ATAD2 enhances the efficacy of DNAdamaging chemotherapy agents and radiation.
    Oncol Rep. 2020;43:318-327.
    PubMed     Abstract available


    December 2019
  17. SHEVCHENKO JA, Khristin AA, Kurilin VV, Kuznetsova MS, et al
    Autologous dendritic cells and activated cytotoxic Tcells as combination therapy for breast cancer.
    Oncol Rep. 2019 Dec 16. doi: 10.3892/or.2019.7435.
    PubMed     Abstract available


  18. JUNG KH, Lee JH, Park JW, Moon SH, et al
    Troglitazone exerts metabolic and antitumor effects on T47D breast cancer cells by suppressing mitochondrial pyruvate availability.
    Oncol Rep. 2019 Dec 16. doi: 10.3892/or.2019.7436.
    PubMed     Abstract available


  19. ZHAO C, Zheng S, Yan Z, Deng Z, et al
    CCL18 promotes the invasion and metastasis of breast cancer through Annexin A2.
    Oncol Rep. 2019 Dec 11. doi: 10.3892/or.2019.7426.
    PubMed     Abstract available


    November 2019
  20. WU H, Wang Q, Zhong H, Li L, et al
    Differentially expressed microRNAs in exosomes of patients with breast cancer revealed by nextgeneration sequencing.
    Oncol Rep. 2019 Nov 6. doi: 10.3892/or.2019.7401.
    PubMed     Abstract available


  21. TRIVIZAKIS E, Ioannidis GS, Melissianos VD, Papadakis GZ, et al
    A novel deep learning architecture outperforming 'offtheshelf' transfer learning and featurebased methods in the automated assessment of mammographic breast density.
    Oncol Rep. 2019;42:2009-2015.
    PubMed     Abstract available


    October 2019
  22. QIN B, Zhao K, Wei J, Wang X, et al
    Novel evidence indicates the presence and replication of hepatitis B virus in breast cancer tissue.
    Oncol Rep. 2019 Oct 30. doi: 10.3892/or.2019.7393.
    PubMed     Abstract available


  23. CUI Y, Fan Y, Zhao G, Zhang Q, et al
    Novel lncRNA PSMG3AS1 functions as a miR1433p sponge to increase the proliferation and migration of breast cancer cells.
    Oncol Rep. 2019 Oct 25. doi: 10.3892/or.2019.7390.
    PubMed     Abstract available


  24. WANG JJ, Huang YQ, Song W, Li YF, et al
    Comprehensive analysis of the lncRNAassociated competing endogenous RNA network in breast cancer.
    Oncol Rep. 2019 Oct 15. doi: 10.3892/or.2019.7374.
    PubMed     Abstract available


  25. XIAO S, Zhu H, Luo J, Wu Z, et al
    miR4255p is associated with poor prognosis in patients with breast cancer and promotes cancer cell progression by targeting PTEN.
    Oncol Rep. 2019 Oct 14. doi: 10.3892/or.2019.7371.
    PubMed     Abstract available


  26. ABE M, Kagara N, Miyake T, Tanei T, et al
    Highly sensitive detection of sentinel lymph node metastasis of breast cancer by digital PCR for RASSF1A methylation.
    Oncol Rep. 2019 Oct 10. doi: 10.3892/or.2019.7363.
    PubMed     Abstract available


  27. NAOI Y, Saito Y, Kishi K, Shimoda M, et al
    Development of recurrence risk score using 95gene classifier and its application to formalinfixed paraffinembedded tissues in ERpositive, HER2negative and nodenegative breast cancer.
    Oncol Rep. 2019 Oct 7. doi: 10.3892/or.2019.7358.
    PubMed     Abstract available


  28. AN G, Wu F, Huang S, Feng L, et al
    Effects of CCL5 on the biological behavior of breast cancer and the mechanisms of its interaction with tumorassociated macrophages.
    Oncol Rep. 2019 Oct 1. doi: 10.3892/or.2019.7344.
    PubMed     Abstract available


    September 2019
  29. DAI X, Chen X, Hakizimana O, Mei Y, et al
    Genetic interactions between ANLN and KDR are prognostic for breast cancer survival.
    Oncol Rep. 2019 Sep 24. doi: 10.3892/or.2019.7332.
    PubMed     Abstract available


  30. HUO H, Ye X, Yang H, Li Q, et al
    RSK4 inhibits breast cancer cell proliferation and invasion in vitro, and is correlated with estrogen receptor upregulation in breast cancer.
    Oncol Rep. 2019 Sep 20. doi: 10.3892/or.2019.7328.
    PubMed     Abstract available


    August 2019
  31. CHEN P, Feng Y, Zhang H, Shi X, et al
    MicroRNA192 inhibits cell proliferation and induces apoptosis in human breast cancer by targeting caveolin 1.
    Oncol Rep. 2019 Aug 30. doi: 10.3892/or.2019.7298.
    PubMed     Abstract available


  32. ZHANG W, Xu J, Wang K, Tang X, et al
    miR1393p suppresses the invasion and migration properties of breast cancer cells by targeting RAB1A.
    Oncol Rep. 2019 Aug 29. doi: 10.3892/or.2019.7297.
    PubMed     Abstract available


  33. WANG Z, Zhang M, Shan R, Wang YJ, et al
    MTMR3 is upregulated in patients with breast cancer and regulates proliferation, cell cycle progression and autophagy in breast cancer cells.
    Oncol Rep. 2019 Aug 23. doi: 10.3892/or.2019.7292.
    PubMed     Abstract available


  34. SUN Q, Fu Q, Li S, Li J, et al
    Emetine exhibits anticancer activity in breast cancer cells as an antagonist of Wnt/betacatenin signaling.
    Oncol Rep. 2019 Aug 22. doi: 10.3892/or.2019.7290.
    PubMed     Abstract available


  35. PAN H, Zheng Y, Pan Q, Chen H, et al
    Expression of LXRbeta, ABCA1 and ABCG1 in human triplenegative breast cancer tissues.
    Oncol Rep. 2019 Aug 14. doi: 10.3892/or.2019.7279.
    PubMed     Abstract available


  36. KATSUTA E, Maawy AA, Yan L, Takabe K, et al
    High expression of bone morphogenetic protein (BMP) 6 and BMP7 are associated with higher immune cell infiltration and better survival in estrogen receptorpositive breast cancer.
    Oncol Rep. 2019 Aug 12. doi: 10.3892/or.2019.7275.
    PubMed     Abstract available


  37. GORNOWICZ A, Szymanowski W, Bielawska A, Szymanowska A, et al
    Monoclonal antiMUC1 antibody with novel octahydropyrazino[2,1a:5,4a']diisoquinoline derivative as a potential multitargeted strategy in MCF7 breast cancer cells.
    Oncol Rep. 2019 Aug 2. doi: 10.3892/or.2019.7256.
    PubMed     Abstract available


    July 2019
  38. FAN C, Liu N, Fan S, Yang Z, et al
    Comprehensive multigene mutation spectra of breast cancer patients from Northeast China obtained using the Ion Torrent sequencing platform.
    Oncol Rep. 2019 Jul 30. doi: 10.3892/or.2019.7253.
    PubMed     Abstract available


  39. HONG Z, Hong C, Ma B, Wang Q, et al
    MicroRNA1263p inhibits the proliferation, migration, invasion, and angiogenesis of triplenegative breast cancer cells by targeting RGS3.
    Oncol Rep. 2019 Jul 26. doi: 10.3892/or.2019.7251.
    PubMed     Abstract available


  40. ZADA S, Hwang JS, Ahmed M, Lai TH, et al
    Protein kinase A activation by betaLapachone is associated with apoptotic cell death in NQO1overexpressing breast cancer cells.
    Oncol Rep. 2019 Jul 19. doi: 10.3892/or.2019.7243.
    PubMed     Abstract available


  41. WANG Y, Wang Y, Wang N, You L, et al
    Poly(ADPribose) polymerase 1/2 inhibitors decrease the ubiquitination of ALC1 mediated by CHFR in breast cancer.
    Oncol Rep. 2019 Jul 18. doi: 10.3892/or.2019.7242.
    PubMed     Abstract available


  42. KONGSEMA M, Wongkhieo S, Khongkow M, Lam EW, et al
    Molecular mechanism of Forkhead box M1 inhibition by thiostrepton in breast cancer cells.
    Oncol Rep. 2019 Jul 8. doi: 10.3892/or.2019.7225.
    PubMed     Abstract available


    June 2019
  43. DING W, Li D, Zhang P, Shi L, et al
    Mutual editing of alternative splicing between breast cancer cells and macrophages.
    Oncol Rep. 2019 Jun 18. doi: 10.3892/or.2019.7200.
    PubMed     Abstract available


  44. YU H, Yang C, Jian L, Guo S, et al
    Sulfasalazineinduced ferroptosis in breast cancer cells is reduced by the inhibitory effect of estrogen receptor on the transferrin receptor.
    Oncol Rep. 2019 Jun 6. doi: 10.3892/or.2019.7189.
    PubMed     Abstract available


  45. KAKIZAWA N, Suzuki K, Abe I, Endo Y, et al
    High relative levels of satellite alpha transcripts predict increased risk of bilateral breast cancer and multiple primary cancer in patients with breast cancer and lacking BRCArelated clinical features.
    Oncol Rep. 2019 Jun 3. doi: 10.3892/or.2019.7182.
    PubMed     Abstract available


    May 2019
  46. MESSEHA SS, Zarmouh NO, Mendonca P, Alwagdani H, et al
    Effects of gossypol on apoptosisrelated gene expression in racially distinct triplenegative breast cancer cells.
    Oncol Rep. 2019 May 31. doi: 10.3892/or.2019.7179.
    PubMed     Abstract available


  47. WU M, Sun Q, Mo CH, Pang JS, et al
    Prospective molecular mechanism of COL5A1 in breast cancer based on a microarray, RNA sequencing and immunohistochemistry.
    Oncol Rep. 2019 May 3. doi: 10.3892/or.2019.7147.
    PubMed     Abstract available


    April 2019
  48. HORGAN XJ, Tatum H, Brannan E, Paull DH, et al
    Resveratrol analogues surprisingly effective against triplenegative breast cancer, independent of ERalpha.
    Oncol Rep. 2019 Apr 16. doi: 10.3892/or.2019.7122.
    PubMed     Abstract available


  49. CHENG Z, Wei W, Wu Z, Wang J, et al
    ARPC2 promotes breast cancer proliferation and metastasis.
    Oncol Rep. 2019 Apr 12. doi: 10.3892/or.2019.7113.
    PubMed     Abstract available


  50. GARCIA-GARCIA F, Salinas-Vera YM, Garcia-Vazquez R, Marchat LA, et al
    miR1455p is associated with pathological complete response to neoadjuvant chemotherapy and impairs cell proliferation by targeting TGFbetaR2 in breast cancer.
    Oncol Rep. 2019 Apr 5. doi: 10.3892/or.2019.7102.
    PubMed     Abstract available


  51. FAN C, Liu N
    Identification of dysregulated microRNAs associated with diagnosis and prognosis in triplenegative breast cancer: An in silico study.
    Oncol Rep. 2019 Apr 2. doi: 10.3892/or.2019.7094.
    PubMed     Abstract available


    March 2019
  52. CHEN S, Li YQ, Yin XZ, Li SZ, et al
    Recombinant adenoviruses expressing apoptin suppress the growth of MCF7 breast cancer cells and affect cell autophagy.
    Oncol Rep. 2019 Mar 18. doi: 10.3892/or.2019.7077.
    PubMed     Abstract available


  53. SHI R, Wang C, Fu N, Liu L, et al
    Downregulation of cytokeratin 18 enhances BCRP-mediated multidrug resistance through induction of epithelial-mesenchymal transition and predicts poor prognosis in breast cancer.
    Oncol Rep. 2019 Mar 15. doi: 10.3892/or.2019.7069.
    PubMed     Abstract available


  54. XIE Q, Wang S, Zhao Y, Zhang Z, et al
    MicroRNA-216a suppresses the proliferation and migration of human breast cancer cells via the Wnt/beta-catenin signaling pathway.
    Oncol Rep. 2019 Mar 7. doi: 10.3892/or.2019.7050.
    PubMed     Abstract available


  55. LU S, Du Y, Cui F, Feng X, et al
    Downregulation of BAG1 in T47D cells promotes resistance to tamoxifen via activation of the PI3K/Akt/mTOR signaling pathway.
    Oncol Rep. 2019;41:1901-1910.
    PubMed     Abstract available


  56. ZHANG M, Liu Q, Li L, Ning J, et al
    Cytoplasmic MCSF facilitates apoptosis resistance by inhibiting the HIF1alpha/BNIP3/Bax signalling pathway in MCF7 cells.
    Oncol Rep. 2019;41:1807-1816.
    PubMed     Abstract available


    February 2019
  57. CHEN Y, He Y, Wang X, Lu F, et al
    Adiposederived mesenchymal stem cells exhibit tumor tropism and promote tumorsphere formation of breast cancer cells.
    Oncol Rep. 2019 Feb 15. doi: 10.3892/or.2019.7018.
    PubMed     Abstract available


  58. DAI X, Geng F, Li M, Liu M, et al
    Tripartite motifcontaining 11 regulates the proliferation and apoptosis of breast cancer cells.
    Oncol Rep. 2019 Feb 14. doi: 10.3892/or.2019.7015.
    PubMed     Abstract available


  59. JAERAPONG N, Jamil QA, Riha J, Milovanovic D, et al
    Organic aniontransporting polypeptides contribute to the uptake of curcumin and its main metabolites by human breast cancer cells: Impact on antitumor activity.
    Oncol Rep. 2019 Feb 14. doi: 10.3892/or.2019.7011.
    PubMed     Abstract available


  60. GUTTLER A, Theuerkorn K, Riemann A, Wichmann H, et al
    Cellular and radiobiological effects of carbonic anhydrase IX in human breast cancer cells.
    Oncol Rep. 2019 Feb 5. doi: 10.3892/or.2019.7001.
    PubMed     Abstract available


  61. MA Z, Liu X, Zhang Q, Yu Z, et al
    Carvedilol suppresses malignant proliferation of mammary epithelial cells through inhibition of the ROSmediated PI3K/AKT signaling pathway.
    Oncol Rep. 2019;41:811-818.
    PubMed     Abstract available


    January 2019
  62. FONTES-SOUSA M, Amorim M, Salta S, Palma De Sousa S, et al
    Predicting resistance to endocrine therapy in breast cancer: It's time for epigenetic biomarkers (Review).
    Oncol Rep. 2019 Jan 11. doi: 10.3892/or.2019.6967.
    PubMed     Abstract available


  63. WEI CW, Yu YL, Chen YH, Hung YT, et al
    Anticancer effects of methotrexate in combination with alphatocopherol and alphatocopherol succinate on triplenegative breast cancer.
    Oncol Rep. 2019 Jan 9. doi: 10.3892/or.2019.6958.
    PubMed     Abstract available


  64. SCHRODER L, Marahrens P, Koch JG, Heidegger H, et al
    Effects of green tea, matcha tea and their components epigallocatechin gallate and quercetin on MCF7 and MDA-MB-231 breast carcinoma cells.
    Oncol Rep. 2019;41:387-396.
    PubMed     Abstract available


    December 2018
  65. MA J, Niu W, Wang X, Zhou Y, et al
    Bromodomaincontaining protein 7 sensitizes breast cancer cells to paclitaxel by activating Bcl2antagonist/killer protein.
    Oncol Rep. 2018 Dec 21. doi: 10.3892/or.2018.6951.
    PubMed     Abstract available


  66. KIM S, You D, Jeong Y, Yu J, et al
    TP53 upregulates alphasmooth muscle actin expression in tamoxifenresistant breast cancer cells.
    Oncol Rep. 2018 Dec 6. doi: 10.3892/or.2018.6910.
    PubMed     Abstract available


  67. HUANG S, Yuan N, Wang G, Wu F, et al
    Cellular communication promotes mammosphere growth and collective invasion through microtubulelike structures and angiogenesis.
    Oncol Rep. 2018;40:3297-3312.
    PubMed     Abstract available


    November 2018
  68. JING X, Liang H, Hao C, Yang X, et al
    Overexpression of MUC1 predicts poor prognosis in patients with breast cancer.
    Oncol Rep. 2018 Nov 27. doi: 10.3892/or.2018.6887.
    PubMed     Abstract available


  69. YAO R, Wang Y, Han D, Ma Y, et al
    Lysines 207 and 325 methylation of WDR5 catalyzed by SETD6 promotes breast cancer cell proliferation and migration.
    Oncol Rep. 2018;40:3069-3077.
    PubMed     Abstract available


  70. HUANG XJ, Xia Y, He GF, Zheng LL, et al
    MALAT1 promotes angiogenesis of breast cancer.
    Oncol Rep. 2018;40:2683-2689.
    PubMed     Abstract available


  71. HENG ZSL, Lee JY, Subhramanyam CS, Wang C, et al
    The role of 17betaestradiolinduced upregulation of Piwilike 4 in modulating gene expression and motility in breast cancer cells.
    Oncol Rep. 2018;40:2525-2535.
    PubMed     Abstract available


  72. YANG PJ, Hou MF, Tsai EM, Liang SS, et al
    Breast cancer is associated with methylation and expression of the a disintegrin and metalloproteinase domain 33 (ADAM33) gene affected by endocrinedisrupting chemicals.
    Oncol Rep. 2018;40:2766-2777.
    PubMed     Abstract available


  73. ZHU L, Li XX, Shi L, Wu J, et al
    Rapamycin enhances the sensitivity of ERpositive breast cancer cells to tamoxifen by upregulating p73 expression.
    Oncol Rep. 2018 Nov 1. doi: 10.3892/or.2018.6842.
    PubMed     Abstract available


  74. KIM MH, Park JW, Lee EJ, Kim S, et al
    C16ceramide and sphingosine 1phosphate/S1PR2 have opposite effects on cell growth through mTOR signaling pathway regulation.
    Oncol Rep. 2018;40:2977-2987.
    PubMed     Abstract available


    October 2018
  75. XIE WY, He RH, Zhang J, He YJ, et al
    betablockers inhibit the viability of breast cancer cells by regulating the ERK/COX2 signaling pathway and the drug response is affected by ADRB2 singlenucleotide polymorphisms.
    Oncol Rep. 2018 Oct 29. doi: 10.3892/or.2018.6830.
    PubMed     Abstract available


  76. EL-TABBA' RM, Mathew P, Masocha W, Khajah MA, et al
    COL3 enhances the antiproliferative and proapoptotic effects of paclitaxel in breast cancer cells.
    Oncol Rep. 2018 Oct 22. doi: 10.3892/or.2018.6815.
    PubMed     Abstract available


  77. LI W, Yang H, Li X, Han L, et al
    Signaling pathway inhibitors target breast cancer stem cells in triple-negative breast cancer.
    Oncol Rep. 2018 Oct 18. doi: 10.3892/or.2018.6805.
    PubMed     Abstract available


  78. WANG L, Shi H, Zhang X, Zhang X, et al
    I157172, a novel inhibitor of cystathionine gamma-lyase, inhibits growth and migration of breast cancer cells via SIRT1-mediated deacetylation of STAT3.
    Oncol Rep. 2018 Oct 16. doi: 10.3892/or.2018.6798.
    PubMed     Abstract available


  79. ZHAO Y, Onda K, Sugiyama K, Yuan B, et al
    Antitumor effects of arsenic disulfide on the viability, migratory ability, apoptosis and autophagy of breast cancer cells.
    Oncol Rep. 2018 Oct 9. doi: 10.3892/or.2018.6780.
    PubMed     Abstract available


  80. SHETTAR A, Damineni S, Mukherjee G, Kondaiah P, et al
    Gap junction beta2 expression is negatively associated with the estrogen receptor status in breast cancer tissues and is a regulator of breast tumorigenesis.
    Oncol Rep. 2018 Oct 3. doi: 10.3892/or.2018.6764.
    PubMed     Abstract available


  81. ZHU L, Zhou W, Zhu X, Xiang S, et al
    Inhibitor of apoptosis proteinlike protein2: A novel growth accelerator for breast cancer cells.
    Oncol Rep. 2018;40:2047-2055.
    PubMed     Abstract available


  82. JIN ZQ, Hao J, Yang X, He JH, et al
    Higenamine enhances the antitumor effects of cucurbitacin B in breast cancer by inhibiting the interaction of AKT and CDK2.
    Oncol Rep. 2018;40:2127-2136.
    PubMed     Abstract available


  83. ZHUO Y, Li X, Zheng Q, Fan X, et al
    Estrogen enhances tumor growth and angiogenesis indirectly via mediation of bone marrowderived cells as well as directly through stimulation of tumor and endothelial cells.
    Oncol Rep. 2018;40:2147-2156.
    PubMed     Abstract available


  84. NETSIRISAWAN P, Chaiyawat P, Chokchaichamnankit D, Lirdprapamongkol K, et al
    Decreasing O-GlcNAcylation affects the malignant transformation of MCF-7 cells via Hsp27 expression and its O-GlcNAc modification.
    Oncol Rep. 2018;40:2193-2205.
    PubMed     Abstract available


  85. ALSAMMAN K, El-Masry OS
    Staurosporine alleviates cisplatin chemoresistance in human cancer cell models by suppressing the induction of SQSTM1/p62.
    Oncol Rep. 2018;40:2157-2162.
    PubMed     Abstract available


  86. SUN X, Zhang H, Zhang Y, Yang Q, et al
    Caspase-dependent mitochondrial apoptotic pathway is involved in astilbin-mediated cytotoxicity in breast carcinoma cells.
    Oncol Rep. 2018;40:2278-2286.
    PubMed     Abstract available


  87. LIAO S, Gan L, Qin W, Liu C, et al
    Inhibition of GSK3 and MEK induced cancer stem cell generation via the Wnt and MEK signaling pathways.
    Oncol Rep. 2018;40:2005-2013.
    PubMed     Abstract available


    September 2018
  88. XIE D, Song H, Wu T, Li D, et al
    MicroRNA424 serves an antioncogenic role by targeting cyclindependent kinase 1 in breast cancer cells.
    Oncol Rep. 2018 Sep 27. doi: 10.3892/or.2018.6741.
    PubMed     Abstract available


  89. CHEN J, Tian W, He H, Chen F, et al
    Downregulation of miR200c3p contributes to the resistance of breast cancer cells to paclitaxel by targeting SOX2.
    Oncol Rep. 2018 Sep 26. doi: 10.3892/or.2018.6735.
    PubMed     Abstract available


  90. WANG YJ, Zheng LY, Wang ZF, Song R, et al
    Associations of genewide SNPs in SNAI1 and TWIST1 with breast cancer and ovarian cancer susceptibility among Chinese Han women.
    Oncol Rep. 2018 Sep 21. doi: 10.3892/or.2018.6725.
    PubMed     Abstract available


  91. ZHAO H, Yang Q, Hu Y, Zhang J, et al
    Antitumor effects and mechanisms of olaparib in combination with carboplatin and BKM120 on human triplenegative breast cancer cells.
    Oncol Rep. 2018 Sep 20. doi: 10.3892/or.2018.6716.
    PubMed     Abstract available


  92. KO YS, Jin H, Lee JS, Park SW, et al
    Radioresistant breast cancer cells exhibit increased resistance to chemotherapy and enhanced invasive properties due to cancer stem cells.
    Oncol Rep. 2018 Sep 18. doi: 10.3892/or.2018.6714.
    PubMed     Abstract available


    August 2018
  93. CHEN Y, Wei L, Zhang X, Liu X, et al
    3Bromopyruvate sensitizes human breast cancer cells to TRAILinduced apoptosis via the phosphorylated AMPKmediated upregulation of DR5.
    Oncol Rep. 2018 Aug 14. doi: 10.3892/or.2018.6644.
    PubMed     Abstract available


  94. GUAN J, Zhou Y, Mao F, Lin Y, et al
    MicroRNA320a suppresses tumor cell growth and invasion of human breast cancer by targeting insulinlike growth factor 1 receptor.
    Oncol Rep. 2018;40:849-858.
    PubMed     Abstract available


  95. YU Z, Lou L, Zhao Y
    Fibroblast growth factor 18 promotes the growth, migration and invasion of MDAMB231 cells.
    Oncol Rep. 2018;40:704-714.
    PubMed     Abstract available


    July 2018
  96. TAKEMORI T, Kawamoto T, Ueha T, Toda M, et al
    Transcutaneous carbon dioxide application suppresses bone destruction caused by breast cancer metastasis.
    Oncol Rep. 2018 Jul 30. doi: 10.3892/or.2018.6608.
    PubMed     Abstract available


  97. CALAF GM, Ponce-Cusi R, Carrion F
    Curcumin and paclitaxel induce cell death in breast cancer cell lines.
    Oncol Rep. 2018 Jul 26. doi: 10.3892/or.2018.6603.
    PubMed     Abstract available


  98. ZHOU XL, Zeng, Ye YH, Sun SM, et al
    Prognostic values of the inhibitor of DNAbinding family members in breast cancer.
    Oncol Rep. 2018 Jul 23. doi: 10.3892/or.2018.6589.
    PubMed     Abstract available


  99. WANG H, He Z, Xia L, Zhang W, et al
    PSMB4 overexpression enhances the cell growth and viability of breast cancer cells leading to a poor prognosis.
    Oncol Rep. 2018 Jul 20. doi: 10.3892/or.2018.6588.
    PubMed     Abstract available


  100. LI S, Dai H, He Y, Peng S, et al
    BMP9 inhibits the growth of breast cancer cells by downregulation of the PI3K/Akt signaling pathway.
    Oncol Rep. 2018 Jul 13. doi: 10.3892/or.2018.6572.
    PubMed     Abstract available


  101. JI Y, Jiang Q, Jian G, Sun H, et al
    Developing a radiosensitivity gene signature for Caucasian patients with breast cancer.
    Oncol Rep. 2018 Jul 12. doi: 10.3892/or.2018.6567.
    PubMed     Abstract available


    June 2018
  102. CANZONERI R, Rabassa ME, Gurruchaga A, Ferretti V, et al
    Alternative splicing variant of RHBDD2 is associated with cell stress response and breast cancer progression.
    Oncol Rep. 2018 Jun 14. doi: 10.3892/or.2018.6489.
    PubMed     Abstract available


  103. ZHAO W, Kuai X, Zhou X, Jia L, et al
    Trop2 is a potential biomarker for the promotion of EMT in human breast cancer.
    Oncol Rep. 2018 Jun 14. doi: 10.3892/or.2018.6496.
    PubMed     Abstract available


  104. VAKLAVAS C, Zinn KR, Samuel SL, Meng Z, et al
    Translational control of the undifferentiated phenotype in ERpositive breast tumor cells: Cytoplasmic localization of ERalpha and impact of IRES inhibition.
    Oncol Rep. 2018;39:2482-2498.
    PubMed     Abstract available


  105. ZHANG GM, Goyal H, Song LL
    Bioinformatics analysis of differentially expressed miRNA-related mRNAs and their prognostic value in breast carcinoma.
    Oncol Rep. 2018;39:2865-2872.
    PubMed     Abstract available


    May 2018
  106. CHOI JW, Moon BI, Lee JW, Kim HJ, et al
    Use of CA153 for screening breast cancer: An antibodylectin sandwich assay for detecting glycosylation of CA153 in sera.
    Oncol Rep. 2018 May 10. doi: 10.3892/or.2018.6433.
    PubMed     Abstract available


  107. WANG Y, Guo L, Feng L, Zhang W, et al
    Single nucleotide variant profiles of viable single circulating tumour cells reveal CTC behaviours in breast cancer.
    Oncol Rep. 2018;39:2147-2159.
    PubMed     Abstract available


  108. XU L, Che X, Wu Y, Song N, et al
    SIRT5 as a biomarker for response to anthracycline-taxane-based neoadjuvant chemotherapy in triple-negative breast cancer.
    Oncol Rep. 2018;39:2315-2323.
    PubMed     Abstract available


  109. NUVOLI S, Galassi S, Gelo I, Rocchitta G, et al
    The role of molecular breast imaging in predicting complete tumor response to treatment and residual tumor extent following neoadjuvant therapy.
    Oncol Rep. 2018;39:2055-2062.
    PubMed     Abstract available


    April 2018
  110. WANG Y, Zhang Z, Wang J
    MicroRNA-384 inhibits the progression of breast cancer by targeting ACVR1.
    Oncol Rep. 2018 Apr 20. doi: 10.3892/or.2018.6385.
    PubMed     Abstract available


  111. CALAF GM, Ponce-Cusi R, Abarca-Quinones J
    Effect of curcumin on the cell surface markers CD44 and CD24 in breast cancer.
    Oncol Rep. 2018 Apr 20. doi: 10.3892/or.2018.6386.
    PubMed     Abstract available


  112. WANG X, Qiu H, Tang R, Song H, et al
    miR30a inhibits epithelialmesenchymal transition and metastasis in triplenegative breast cancer by targeting ROR1.
    Oncol Rep. 2018 Apr 18. doi: 10.3892/or.2018.6379.
    PubMed     Abstract available


  113. TOPCUL M, Ceti N IL, Ozbas Turan S, Kolusayin Ozar MO, et al
    In vitro cytotoxic effect of PARP inhibitor alone and in combination with nabpaclitaxel on triplenegative and luminal A breast cancer cells.
    Oncol Rep. 2018 Apr 12. doi: 10.3892/or.2018.6364.
    PubMed     Abstract available


  114. LUO T, Yan Y, He Q, Ma X, et al
    miR-328-5p inhibits MDA-MB-231 breast cancer cell proliferation by targeting RAGE.
    Oncol Rep. 2018 Apr 4. doi: 10.3892/or.2018.6353.
    PubMed     Abstract available


  115. SHEN Y, Zhong J, Liu J, Liu K, et al
    Protein arginine N-methyltransferase 2 reverses tamoxifen resistance in breast cancer cells through suppression of ER-alpha36.
    Oncol Rep. 2018 Apr 2. doi: 10.3892/or.2018.6350.
    PubMed     Abstract available


  116. OH YJ, Park SY, Seo YH
    The targeted inhibition of Hsp90 by a synthetic small molecule, DPide offers an effective treatment strategy against TNBCs.
    Oncol Rep. 2018;39:1775-1782.
    PubMed     Abstract available


    March 2018
  117. LEON-GALICIA I, Diaz-Chavez J, Albino-Sanchez ME, Garcia-Villa E, et al
    Resveratrol decreases Rad51 expression and sensitizes cisplatinresistant MCF7 breast cancer cells.
    Oncol Rep. 2018 Mar 27. doi: 10.3892/or.2018.6336.
    PubMed     Abstract available


  118. LIN CC, Lo MC, Moody RR, Stevers NO, et al
    Doxycycline targets aldehyde dehydrogenasepositive breast cancer stem cells.
    Oncol Rep. 2018 Mar 27. doi: 10.3892/or.2018.6337.
    PubMed     Abstract available


  119. LIU M, Liu H, Chen J
    Mechanisms of the CDK4/6 inhibitor palbociclib (PD 0332991) and its future application in cancer treatment (Review).
    Oncol Rep. 2018;39:901-911.
    PubMed     Abstract available


    February 2018
  120. RATHINAVELU A, Kanagasabai T, Dhandayuthapani S, Alhazzani K, et al
    Anti-angiogenic and pro-apoptotic effects of a small-molecule JFD-WS in in vitro and breast cancer xenograft mouse models.
    Oncol Rep. 2018 Feb 9. doi: 10.3892/or.2018.6256.
    PubMed     Abstract available


  121. SHENG C, Qiu J, He Z, Wang H, et al
    Suppression of Kpnbeta1 expression inhibits human breast cancer cell proliferation by abrogating nuclear transport of Her2.
    Oncol Rep. 2018;39:554-564.
    PubMed     Abstract available


    January 2018
  122. HU B, Meng X, Zhang Y, Hossain MM, et al
    Short hairpin RNA-mediated gene silencing of ADAM17 inhibits the growth of breast cancer MCF7 cells in vitro and in vivo and its mechanism of action.
    Oncol Rep. 2018 Jan 26. doi: 10.3892/or.2018.6237.
    PubMed     Abstract available


  123. YIN G, Zeng B, Peng Z, Liu Y, et al
    Synthesis and application of 131I-fulvestrant as a targeted radiation drug for endocrine therapy in human breast cancer.
    Oncol Rep. 2018 Jan 11. doi: 10.3892/or.2018.6212.
    PubMed     Abstract available


  124. WANG YW, Zhang W, Ma R
    Bioinformatic identification of chemoresistance-associated microRNAs in breast cancer based on microarray data.
    Oncol Rep. 2018 Jan 10. doi: 10.3892/or.2018.6205.
    PubMed     Abstract available


  125. ZHAO M, Wang Y, Du C, Liu Y, et al
    Aspirin and metformin exhibit antitumor activity in murine breast cancer.
    Oncol Rep. 2018 Jan 4. doi: 10.3892/or.2018.6190.
    PubMed     Abstract available


  126. KASORN A, Loison F, Kangsamaksin T, Jongrungruangchok S, et al
    Terrein inhibits migration of human breast cancer cells via inhibition of the Rho and Rac signaling pathways.
    Oncol Rep. 2018 Jan 4. doi: 10.3892/or.2018.6189.
    PubMed     Abstract available


    December 2017
  127. WANG Y, Li L, Wang H, Li J, et al
    Silencing TGIF suppresses migration, invasion and metastasis of MDAMB231 human breast cancer cells.
    Oncol Rep. 2017 Dec 4. doi: 10.3892/or.2017.6133.
    PubMed     Abstract available


    November 2017
  128. LIN SC, Chu PY, Liao WT, Wu MY, et al
    Glycyrrhizic acid induces human MDA-MB-231 breast cancer cell death and autophagy via the ROS-mitochondrial pathway.
    Oncol Rep. 2017 Nov 29. doi: 10.3892/or.2017.6123.
    PubMed     Abstract available


  129. ANDROUTSOPOULOS VP, Spandidos DA
    Anticancer pyridines induce G2/M arrest and apoptosis via p53 and JNK upregulation in liver and breast cancer cells.
    Oncol Rep. 2017 Nov 28. doi: 10.3892/or.2017.6116.
    PubMed     Abstract available


  130. SUI Y, Zhang X, Yang H, Wei W, et al
    MicroRNA-133a acts as a tumour suppressor in breast cancer through targeting LASP1.
    Oncol Rep. 2017 Nov 27. doi: 10.3892/or.2017.6114.
    PubMed     Abstract available


  131. QIU N, He Y, Zhang S, Hu X, et al
    Cullin 7 is a predictor of poor prognosis in breast cancer patients and is involved in the proliferation and invasion of breast cancer cells by regulating the cell cycle and microtubule stability.
    Oncol Rep. 2017 Nov 21. doi: 10.3892/or.2017.6106.
    PubMed     Abstract available


  132. AOTO K, Mimura K, Okayama H, Saito M, et al
    Immunogenic tumor cell death induced by chemotherapy in patients with breast cancer and esophageal squamous cell carcinoma.
    Oncol Rep. 2017 Nov 14. doi: 10.3892/or.2017.6097.
    PubMed     Abstract available


  133. ZHANG W, Pan Y, Gou P, Zhou C, et al
    Effect of xanthohumol on Th1/Th2 balance in a breast cancer mouse model.
    Oncol Rep. 2017 Nov 13. doi: 10.3892/or.2017.6094.
    PubMed     Abstract available


  134. QIU Y, Liu Y, Li WH, Zhang HQ, et al
    P2Y2 receptor promotes the migration and invasion of breast cancer cells via EMT-related genes Snail and E-cadherin.
    Oncol Rep. 2017 Nov 7. doi: 10.3892/or.2017.6081.
    PubMed     Abstract available


  135. GONZALEZ-GONZALEZ A, Gonzalez A, Alonso-Gonzalez C, Menendez-Menendez J, et al
    Complementary actions of melatonin on angiogenic factors, the angiopoietin/Tie2 axis and VEGF, in cocultures of human endothelial and breast cancer cells.
    Oncol Rep. 2017 Nov 2. doi: 10.3892/or.2017.6070.
    PubMed     Abstract available


  136. REN P, Ren X, Cheng L, Xu L, et al
    Frankincense, pine needle and geranium essential oils suppress tumor progression through the regulation of the AMPK/mTOR pathway in breast cancer.
    Oncol Rep. 2017 Nov 1. doi: 10.3892/or.2017.6067.
    PubMed     Abstract available


    October 2017
  137. JIANG Y, Ji F, Liu Y, He M, et al
    Cisplatin-induced autophagy protects breast cancer cells from apoptosis by regulating yes-associated protein.
    Oncol Rep. 2017 Oct 16. doi: 10.3892/or.2017.6035.
    PubMed     Abstract available


  138. HOU W, Zhang H, Bai X, Liu X, et al
    Suppressive role of miR-592 in breast cancer by repressing TGF-beta2.
    Oncol Rep. 2017 Oct 12. doi: 10.3892/or.2017.6029.
    PubMed     Abstract available


  139. HE DX, Wu XL, Lu CX, Gu XT, et al
    Genome-wide analysis of the three-way interplay among gene expression, estrogen receptor expression and chemotherapeutic sensitivity in breast cancer.
    Oncol Rep. 2017 Oct 12. doi: 10.3892/or.2017.6033.
    PubMed     Abstract available


  140. YANG L, Song Z, Wang X, Yang W, et al
    Huaier extract enhances the treatment efficacy of paclitaxel in breast cancer cells via the NF-kappaB/IkappaBalpha pathway.
    Oncol Rep. 2017 Oct 12. doi: 10.3892/or.2017.6024.
    PubMed     Abstract available


  141. HAN Y, Zhang L, Wang W, Li J, et al
    Livin promotes the progression and metastasis of breast cancer through the regulation of epithelialmesenchymal transition via the p38/GSK3beta pathway.
    Oncol Rep. 2017 Oct 10. doi: 10.3892/or.2017.6017.
    PubMed     Abstract available


    September 2017
  142. ZHOU T, Zhang A, Kuang G, Gong X, et al
    Baicalin inhibits the metastasis of highly aggressive breast cancer cells by reversing epithelial-to-mesenchymal transition by targeting beta-catenin signaling.
    Oncol Rep. 2017 Sep 28. doi: 10.3892/or.2017.6011.
    PubMed     Abstract available


  143. ONO H, Iizumi Y, Goi W, Sowa Y, et al
    Ribosomal protein S3 regulates XIAP expression independently of the NF-kappaB pathway in breast cancer cells.
    Oncol Rep. 2017 Sep 27. doi: 10.3892/or.2017.6008.
    PubMed     Abstract available


  144. AN J, Wang L, Zhao Y, Hao Q, et al
    Effects of FSTL1 on cell proliferation in breast cancer cell line MDAMB231 and its brain metastatic variant MDAMB231BR.
    Oncol Rep. 2017 Sep 26. doi: 10.3892/or.2017.6004.
    PubMed     Abstract available


  145. ZHANG Y, Wang DL, Yan HY, Liao JY, et al
    Genome-wide study of ER-regulated lncRNAs shows AP000439.3 may function as a key regulator of cell cycle in breast cancer.
    Oncol Rep. 2017 Sep 20. doi: 10.3892/or.2017.5975.
    PubMed     Abstract available


  146. TANG CP, Zhou HJ, Qin J, Luo Y, et al
    MicroRNA-520c-3p negatively regulates EMT by targeting IL-8 to suppress the invasion and migration of breast cancer.
    Oncol Rep. 2017 Sep 19. doi: 10.3892/or.2017.5968.
    PubMed     Abstract available


  147. ZHAO Y, Ge CC, Wang J, Wu XX, et al
    MEK inhibitor, PD98059, promotes breast cancer cell migration by inducing beta-catenin nuclear accumulation.
    Oncol Rep. 2017 Sep 13. doi: 10.3892/or.2017.5955.
    PubMed     Abstract available


    June 2017
  148. XU W, Wu B, Fu L, Chen J, et al
    Comparison of three different methods for the detection of circulating tumor cells in mice with lung metastasis.
    Oncol Rep. 2017;37:3219-3226.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Breast Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: